Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds

ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued to the Company patent No. 4,934,432, entitled “Quinazoline Derivatives and Therapeutic Use Thereof.” This new patent covers Rexahn’s anti-cancer candidate RX-1792 and related compounds, and a composition for treating anti-proliferative and anti-tumor activities.

Rick Soni, President of Rexahn, noted, “We are very pleased to obtain this additional patent coverage for RX-1792 in Japan, which broadens and strengthens our global intellectual property position. RX-1792 continues to demonstrate exciting anti-proliferative and anti-tumor effects in preclinical studies, and we look forward to accelerating its development.”

Preclinical studies have shown that RX-1792 inhibits in vitro proliferation of cancer cells derived from human solid tumors, including drug-resistant cells, by inhibiting EGFR tyrosine kinase. RX-1792 has also inhibited tumor growth in xenograft human tumor models.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.

Safe Harbor

To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn's plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn's actual results to be materially different than those expressed in or implied by Rexahn's forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of Rexahn's licensees or sublicensees; the success of clinical testing; and Rexahn's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect Rexahn's actual results are described in Rexahn's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Rexahn Pharmaceuticals, Inc.
Investor Relations
Stern Investor Relations, Inc.
Stephanie Ascher, 212-362-1200
[email protected]
or
Base Pair Communications
Constantine Theodoropulos, 617-816-4637
[email protected]

Source: Rexahn Pharmaceuticals, Inc.

Released April 30, 2012